---
figid: PMC10149906__gr1
figtitle: 'Building on the backbone of CD47-based therapy in cancer: Combination strategies,
  mechanisms, and future perspectives'
organisms:
- NA
organisms_ner:
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC10149906
filename: gr1.jpg
figlink: /pmc/articles/PMC10149906/figure/fig1/
number: F1
caption: Combination strategies enhance macrophage phagocytosis. (A) The combination
  treatment enhances phagocytosis by increasing the CRT on the cell surface, or enhancing
  Fc–FcR interaction. Chemotherapeutic drugs or radiotherapy enhance phagocytosis
  by increasing the surface expression of CRT. Some of them induces the ICD of cancer
  cells, cause more DNA damage, activate the cGAS–STING pathway of APC and finally
  leading to T cell activation. Anti-CD20 antibody augments ADCP through Fc–FcR interaction
  after combining with anti-CD47 antibody. Moreover, the up-regulation of CD47 on
  cancer cells by chemotherapy, radiotherapy or anti-VEGF antibody provides the opportunities
  to combine the agents targeting CD47. (B) Some combination strategies enhance macrophage
  phagocytosis by repolarizing the macrophage phenotype from TAMs to M1-like macrophage.
  CIS, cisplatin; TMZ, temozolomide; AZA, azacytidine; DOX, doxorubicin; CD20 Ab,
  anti-CD20 antibody; HER2 Ab, anti-HER2 antibody, CBT, cabazitaxel; OV-αCD47, the
  oncolytic virus expressing an anti-CD47 antibody.
papertitle: 'Building on the backbone of CD47-based therapy in cancer: Combination
  strategies, mechanisms, and future perspectives.'
reftext: Zi-Han Ye, et al. Acta Pharm Sin B. 2023 Apr;13(4):1467-1487.
year: '2023'
doi: 10.1016/j.apsb.2022.12.016
journal_title: Acta Pharmaceutica Sinica. B
journal_nlm_ta: Acta Pharm Sin B
publisher_name: Elsevier
keywords: CD47 | Combination strategies | Bispecific antibodies | Clinical data |
  Preclinical data | Cancer | Mechanisms | Future perspectives
automl_pathway: 0.958648
figid_alias: PMC10149906__F1
figtype: Figure
redirect_from: /figures/PMC10149906__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC10149906__gr1.html
  '@type': Dataset
  description: Combination strategies enhance macrophage phagocytosis. (A) The combination
    treatment enhances phagocytosis by increasing the CRT on the cell surface, or
    enhancing Fc–FcR interaction. Chemotherapeutic drugs or radiotherapy enhance phagocytosis
    by increasing the surface expression of CRT. Some of them induces the ICD of cancer
    cells, cause more DNA damage, activate the cGAS–STING pathway of APC and finally
    leading to T cell activation. Anti-CD20 antibody augments ADCP through Fc–FcR
    interaction after combining with anti-CD47 antibody. Moreover, the up-regulation
    of CD47 on cancer cells by chemotherapy, radiotherapy or anti-VEGF antibody provides
    the opportunities to combine the agents targeting CD47. (B) Some combination strategies
    enhance macrophage phagocytosis by repolarizing the macrophage phenotype from
    TAMs to M1-like macrophage. CIS, cisplatin; TMZ, temozolomide; AZA, azacytidine;
    DOX, doxorubicin; CD20 Ab, anti-CD20 antibody; HER2 Ab, anti-HER2 antibody, CBT,
    cabazitaxel; OV-αCD47, the oncolytic virus expressing an anti-CD47 antibody.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - APCS
  - OPN1SW
  - IFNB1
  - IFNA1
  - STING1
  - CGAS
  - SIRPA
  - NFKB1
  - LRP1
  - C1D
  - CALCR
  - CALR
  - SLC6A8
  - CISH
  - ERBB2
  - APP
  - SUCLA2
  - MS4A1
  - KRT20
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - CD47
  - cbt
  - Sting
  - aub
  - Dif
  - dl
  - Rel
  - crt
  - Calr
  - Rpn3
  - Dox-3
  - ab
  - Appl
  - Pvf1
  - Pvf2
  - Pvf3
  - Pvr
---
